Navigation Links
Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
Date:11/9/2012

PRINCETON, N.J., Nov. 9, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced that Chief Medical Officer, Dr. Michael H. Davidson, recently presented data from the Company's Phase 3 EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial at the Scientific Sessions of the American Heart Association (AHA) in Los Angeles, CA. Dr. Davidson's presentation specifically focused on the effects of Epanova, Omthera's lead, Omega-3 free fatty acid compound for the treatment of patients with hypertriglyceridemia (very high triglycerides), on apolipoprotein C-III (ApoC-III), one of the tertiary endpoints of the EVOLVE study.  Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ApoC-III, a protein component of very low density lipoprotein (VLDL), is an independent predictor of recurrent coronary events and is found to be elevated in patients suffering from very high triglycerides.  

ApoC-III inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich lipoproteins, thereby reducing the conversion of VLDL to LDL and enhancing the formation of more atherogenic small, dense LDL.   Various clinical trials indicate that elevated levels of ApoC-III are an independent risk predictor for coronary heart disease. Lower levels of ApoC-III are associated with lower rates of coronary heart disease, making ApoC-III an important and novel therapeutic target. 

Omthera's EVOLVE trial evaluated 399 patients in four dosing groups: Epanova 2g/day, Epanova 3g/day, Epanova 4g/day and control (olive oil 4g/day).  An analysis of these patients showed statistically significant reductions in ApoC-III of 11% (p=0.022) in the 2g cohort and 14% (p<0.001) in the 4g cohort, compared to olive oil (2%).  

The analysis also showed statistically significant red
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
4. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
7. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
8. Genoa Pharmaceuticals announces $1.2M Financing
9. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
10. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
11. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... S.C., Oct. 21, 2011 Federal, state and local ... growing biomedical research effort with the dedication of a ... for major diseases. The complex, housing 78 ... traditional research approach by combining scientists from different fields ...
... division of Sanofi (EURONEXT: SAN and NYSE: ... study evaluating the immunogenicity and safety of an investigational ... of age and older. Currently licensed influenza vaccines target ... a given year. The data were presented at the ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
(Date:5/21/2013)... Adenotonsillectomy, or the removal of the adenoids and tonsils, ... States, often as a treatment for children with obstructive ... a child,s attention and executive functioning, behavior, sleep apnea ... evaluated until now. A study led by Susan ... Sleep and Cardiovascular Medicine and Associate Clinic Director of ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2
... and other headaches are more likely to have retinopathy, damage ... severe vision problems or blindness, than those without a ... May 15, 2007, issue of Neurology, the scientific journal of ... researchers reviewed the headache history and eye health of 10,902 ...
... and chronic obstructive pulmonary disease among men has discovered ... progressive inflammatory lung disease (COPD). ,COPD (chronic ... progressive lung disease, such as emphysema and bronchitis. ... 43,000 men, who were already part of the US ...
... of infant mortality, cancer, accidental death, and diabetes than any ... according to a state health official, the Sioux Falls Argus ... Health Department, at the request of the Zaniya Task Force, ... of the state's population and found what he called "very ...
... increase the risk of heart attacks and death in patients who ... caused by plaque build-up on the inside walls of the arteries ... them to harden and narrow. This in addition, can ... , According to a report in the Journal of ...
... new research has found that extremely anxious patients with heart ... death when compared to those with a calmer attitude ... were in greatest danger, while those who initially had high ... risk. ,"Most patients come in very anxious about ...
... lay along the Nile in ancient Egypt and not ... the KNH Centre for Biomedical Egyptology at the ... team discovered the evidence in medical papyri written in ... ,"Classical scholars have always considered the ancient Greeks, ...
Cached Medicine News:Health News:Mid-Life Headaches May Increase Risk of Vision Problems 2Health News:American Indians in South Dakota Have More Health Problems Than Others in State, Nationwide, Health Official Says 2Health News:Dont Worry- Be Good To Your Heart 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 3Health News:Modern Medicine Originated in Egypt, Not Greece 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: